The aesthetic consumer isn't necessarily pulling back on spending. Instead, patients appear to be becoming more selective about where their dollars go.
That distinction is one of the key takeaways from Guidepoint Qsight's latest data, which showed total patient spending reaching $7.8 billion in Q2 2026, up 9% year over year after a relatively flat first quarter. Surgical procedures led the acceleration, increasing 19%, while neurotoxins grew 9% and skin rejuvenation continued to post strong gains. Fillers, meanwhile, stabilized after several quarters of decline.
Related: Aesthetic Consumers Are Reallocating Spending Toward Longevity, Maintenance and Skin Health
For Erika Sheyn, SVP of Aesthetics at Guidepoint Qsight, the numbers point to a broader shift in how patients evaluate aesthetic treatments: Consumers are reallocating spending toward procedures they perceive as delivering lasting value, established maintenance benefits or improvements in overall skin quality.
That doesn't mean every category is benefiting equally. Nonsurgical body contouring remains a notable weak spot as GLP-1 medications increasingly address some of the same motivations that historically drove patients toward fat-reduction treatments.
When speaking to MedEsthetics, Sheyn breaks down what the latest data says about the changing aesthetic consumer—and what practices should be watching as 2026 moves into its second half.
Q: Q2 marked a notable acceleration from the relatively modest growth seen in Q1. What changed between the first and second quarters?
Erika Sheyn: Q2 showed a meaningful acceleration, with total patient spending increasing 9% year over year after a relatively flat Q1. The biggest difference was the strength of surgical procedures, which increased 19%, alongside stronger neurotoxin growth and continued momentum in skin rejuvenation. Fillers also stabilized after several quarters of decline.
Taken together, Q2 growth was broader across several major treatment categories than it was in Q1.
Q: Does the data suggest patients are becoming more intentional about how frequently they treat—and where they allocate their budgets?
Sheyn: What we can see is that some of the strongest-performing categories were surgery, neurotoxins and skin rejuvenation, while biostimulatory fillers continued to gain share within fillers.
That spending pattern is consistent with demand for durable outcomes, established maintenance treatments and treatments focused on longer-term skin quality. We are seeing evidence of reallocation across treatment categories rather than evidence of an overall pullback in aesthetic spending.
Q: Skin health and rejuvenation have also been strong. Is skin quality becoming a larger part of patients' overall aesthetic spending?
Sheyn: The latest Q2 results reinforce the broader skin-health momentum Qsight identified earlier this year. We continue to see strong growth across skin rejuvenation, supported by patient interest in treatments that improve overall skin quality, texture and radiance.
This suggests that skin health is becoming an increasingly important part of the aesthetics conversation, with patients placing more value on ongoing maintenance and rejuvenation as part of their overall treatment plans.
Q: Nonsurgical body contouring appears to be the clearest weak spot. How significantly are GLP-1 medications changing that competitive landscape?
Sheyn: GLP-1s are changing the landscape because nonsurgical body contouring is often used for fat reduction or body-shape goals, and weight-loss medications are now addressing some of those same patient motivations.
That does not mean body contouring goes away, but practices may need to be more specific about where these treatments fit. Rather than positioning them as a weight-loss alternative, the opportunity is to focus on contour refinement, stubborn areas, skin laxity and helping patients improve the way their body looks after weight loss.
Q: Looking toward the second half of 2026, which categories appear best positioned—and which should practices be watching more closely?
Sheyn: Based on the categories showing momentum through Q2, neurotoxins, skin rejuvenation, biostimulatory injectables and surgery appear well positioned entering the second half of the year.
Each is currently demonstrating strength or improving performance in the data. Nonsurgical body contouring remains an area to watch given its recent softness and the changing weight-management landscape.
Traditional HA fillers are another category to monitor. Although fillers stabilized in Q2, the continued shift toward biostimulatory products suggests the composition of filler spending is evolving.
Q: Earlier this year, Qsight identified strong growth in professional-grade and regenerative skincare. Does the Q2 data suggest that skin health is continuing that trajectory—or is something broader happening?
Sheyn: Q2 supports the continued strength of skin health, but the broader data suggest the trend extends beyond skincare alone.
Skin rejuvenation continued to grow, while surgery increased 19%, neurotoxins increased 9% and fillers stabilized with biostimulatory products continuing to gain share.
Rather than pointing to one individual category, the Q2 results show spending growth across several different areas of aesthetics. The commonality is that many of the categories performing well are associated with established maintenance, skin quality or more durable outcomes.
The Bigger Picture
Taken together, the Q2 data suggest that the aesthetic consumer isn't abandoning discretionary treatments. Instead, patients may be applying a more critical lens to their spending.
For practices, that distinction matters.
Treatments that can be positioned around maintenance, skin quality, durability or clearly defined outcomes may have an advantage as consumers become more deliberate about their aesthetic investments. Meanwhile, categories facing new competitive alternatives—including nonsurgical body contouring in the era of GLP-1 weight-loss medications—may require practices to rethink both positioning and patient education.
